An interventional study of dosage of blood biomarker miR1 in Duchenne / Becker Muscular Dystrophy, Dystrophia Myotonica 1 and Congenital Myopathies, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Muscular Dystrophy, Duchenne with a site in France — 11 open to participants now, 13 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · France.
Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, this one is the 21st largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2026, is one of 9 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 64th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →11 of the 66 studies in Muscular Dystrophy, Duchenne with a site in France are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in France, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Nantes University Hospital · Sites in France
Ages 5–60 · Men only · Healthy volunteers
Assistance Publique Hopitaux De Marseille · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Italfarmaco · Sites in France, Belgium, Canada and 9 more countries
Ages 9–17 · Men only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 16 · Phase 3 24
First in 2006; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 83 across the 50 interventional studies, 220 across the 15 observational. Of the 46 that completed or were terminated, 18 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 66 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 1 study filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
2 of the studies in Muscular Dystrophy, Duchenne with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833489Assistance Publique Hopitaux De MarseilleTranscriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases | 2026-12-01 |
| NCT06147414Assistance Publique - Hôpitaux de ParisDevelopment of Non-Invasive Prenatal Diagnosis for Single Gene Disorders | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies in Muscular Dystrophy, Duchenne with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases.
MicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease.
The main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: dosage of blood biomarker miR1
Patients and controls will be asked to provide blood samples to evaluate their blood level of miR1 biomarker on a unique time participation.
blood expression level of micro-RNA miR-1
The main goal is to evaluate the interest of miR-1 as a blood biomarker for neuromuscular diseases, specifically muscular dystrophies and congenital myopathies.
Time frame: at a unique time of enrollment
Demographic Correlations
The study will analyze the correlation between blood expression levels of miR-1 and the age and sex of the participants
Time frame: at a unique time of enrollment
Severity correlation
the study will analyse the correlation between miR-1 levels and the clinical severity of the neuromuscular condition. Severity of Myotonic Dystrophy Type 1 (DM1): miR-1 level relation to the severity of the condition, looking at: * The clinical phenotype (based on the age of disease onset). * The number of CTG nucleotide repeats in the DMPK gene,. * The presence of cardiac involvement,. • Severity of Duchenne and Becker Muscular Dystrophies (DMD/DMB): miR-1 levels based on: * The presence of cardiac involvement, * The loss of ambulation (whether the patient has lost the ability to walk)
Time frame: at a unique time of enrollment
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Mar 2029, 37 months after the start.
Of 45 non-industry interventional studies with no phase under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 37 months is above that.
Counting every sponsor, half of 47 studies reached it within 20 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →
University Hospital, Clermont-Ferrand →